Business
MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting
Dr. Phyllis Gardner and James L. Bierman Reelected to Board of Directors Company Also Receives Approvals for Say-on-Pay Proposal and Qualified Employee Stock
About this update from Mimedx Group, Inc
[{"type":"text","content":"Dr. Phyllis Gardner and James L. Bierman Reelected to Board of Directors Company Also Receives Approvals for Say-on-Pay Proposal and Qualified Employee Stock Purchase Plan MARIETTA, Ga., June 07, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that, based on the preliminary vote count provided by its proxy solicitor, shareholders have approved all proposals set forth by the Company at the 2022 Annual Meeting of Shareholders, including the reelection of both of MIMEDX’s directors, Dr. Phyllis Gardner and James L. Bierman, and the proposals on say-on-pay and the Company’s qualified employee stock purchase plan. “Today’s Board and management team have successfully charted a course for future growth,” said MIMEDX’s Chair of the Board, Dr. M. Kathleen Behrens. “The leadership team rebuilt MIMEDX into a stronger, more reputable Company, with a solid foundation and critical infrastructure from which to execute and perform at a higher level moving forward. We thank our shareholders for their strong support of our highly qualified directors at such a pivotal time and appreciate their approval of all of our proposals this year. That said, shareholders have also been clear in their feedback, particularly as it relates to the Company’s executive compensation program, and the Board wants them to know that we have heard them. We remain committed to always evaluating and taking a fresh look at executive pay more broadly, with shareholder perspectives and business performance in mind.” MIMEDX expects to file the final voting results, as tabulated by the independent Inspector of Elections, in a Form 8-K with the Securities and Exchange Commission. About MIMEDX MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using ...